Articles |

Strategies and Options for Minimizing Resistance Emergence in Pulmonary Infections FREE TO VIEW

Sebastian G. B. Amyes
Author and Funding Information

From the Department of Medical Microbiology, The Medical School, University of Edinburgh, Scotland

1998 by the American College of Chest Physicians

Chest. 1998;113(3_Supplement):228S-232S. doi:10.1378/chest.113.3_Supplement.228S
Text Size: A A A
Published online


The early-onset hospital pulmonary Gram-negative infections may respond to ciprofloxacin and co-amoxiclav without significant resistance development. Penicillin-resistant Streptococcus pneumoniae may be treated with macrolides, fluoroquinolones, and glycopeptides. The late-onset hospital pathogens all seem to have developed resistance to cephalosporins, so greater reliance is now made on the fluoroquinolones and carbapenems when aminoglycoside therapy is considered undesirable.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543